{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:25:08Z","timestamp":1794435908176,"version":"4.9.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101156595"],"award-info":[{"award-number":["101156595"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015676","name":"Berlin-Brandenburger Centrum f\u00fcr Regenerative Therapien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013865","name":"Stiftung Charit\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omtn.2026.102929","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:16:27Z","timestamp":1775574987000},"page":"102929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7761-5711","authenticated-orcid":false,"given":"Samira","family":"Picht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00ed","family":"Farrera-Sal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Hiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Brumhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia M.","family":"Klaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schulenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hemmerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif E.","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Dieter","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Gossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5964-9179","authenticated-orcid":false,"given":"Michael","family":"Schmueck-Henneresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6562-2351","authenticated-orcid":false,"given":"Norman M.","family":"Drzeniek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2026.102929_bib1","article-title":"Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.omtn.2026.102929_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.865424","article-title":"Review: Sustainable Clinical Development of CAR-T Cells \u2013 Switching From Viral Transduction Towards CRISPR-Cas Gene Editing","volume":"13","author":"Wagner","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.102929_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102929_bib4","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2026.102929_bib7","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2026.102929_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2026.102929_bib9","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1093\/rheumatology\/keaf077","article-title":"Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis","volume":"64","author":"Albach","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.omtn.2026.102929_bib10","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2026.102929_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell Therapy: A New Era in Cancer Immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102929_bib12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2021.173","article-title":"Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells","volume":"32","author":"Irving","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtn.2026.102929_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omtm.2017.10.001","article-title":"Interactions between Retroviruses and the Host Cell Genome","volume":"8","author":"Poletti","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.102929_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/2277-9175.98152","article-title":"Viral and nonviral delivery systems for gene delivery","volume":"1","author":"Nayerossadat","year":"2012","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.omtn.2026.102929_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","author":"Amini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omtn.2026.102929_bib16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2026.102929_bib17","series-title":"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden","first-page":"433","author":"Santomasso","year":"2019"},{"key":"10.1016\/j.omtn.2026.102929_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib19","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib20","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omtn.2026.102929_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103020","article-title":"Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors","volume":"84","author":"Hong","year":"2023","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.omtn.2026.102929_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omtn.2026.102929_bib23","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ard.2025.06.231","article-title":"POS0876 EFFECT OF ANTI-CD19 CAR T CELL THERAPY IN THE BONE MARROW OF PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2026.102929_bib25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med. Overseas. Ed."},{"key":"10.1016\/j.omtn.2026.102929_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202308447","article-title":"In Vitro Transcribed mRNA Immunogenicity Induces Chemokine-Mediated Lymphocyte Recruitment and Can Be Gradually Tailored by Uridine Modification","volume":"11","author":"Drzeniek","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2026.102929_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121971","article-title":"Immuno-engineered mRNA combined with cell adhesive niche for synergistic modulation of the MSC secretome","volume":"294","author":"Drzeniek","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2026.102929_bib28","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2026.102929_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omtn.2026.102929_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/INMD.20230036","article-title":"mRNA-based chimeric antigen receptor T cell therapy: Basic principles, recent advances and future directions","volume":"2","author":"Xiao","year":"2024","journal-title":"Interdisciplinary Medicine"},{"key":"10.1016\/j.omtn.2026.102929_bib31","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.omtn.2026.102929_bib32","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","article-title":"Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma","volume":"28","author":"Meister","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2026.102929_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102805","article-title":"mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells","volume":"37","author":"Kahwaji","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2026.102929_bib34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2026.102929_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3735","article-title":"The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer","volume":"13","author":"Vollmer","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib36","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.0105-2896.2006.00391.x","article-title":"CD8+ T-cell memory in tumor immunology and immunotherapy","volume":"211","author":"Klebanoff","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omtn.2026.102929_bib37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2026.102929_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12979-019-0165-8","article-title":"Age related human T cell subset evolution and senescence","volume":"16","author":"Li","year":"2019","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.omtn.2026.102929_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.V98.1.49","article-title":"Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells","volume":"98","author":"Van Tendeloo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2026.102929_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymthe.2005.07.688","article-title":"High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation","volume":"13","author":"Zhao","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2026.102929_bib41","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","article-title":"Nonviral RNA chimeric antigen receptor\u2013modified T cells in patients with Hodgkin lymphoma","volume":"132","author":"Svoboda","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2026.102929_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omtn.2026.102929_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23113044","article-title":"A Review on Electroporation-Based Intracellular Delivery","volume":"23","author":"Shi","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2026.102929_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.omtn.2026.102929_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2026.102929_bib46","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2026.102929_bib47","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2026.102929_bib48","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00109-020-01956-1","article-title":"Strategies for simultaneous and successive delivery of RNA","volume":"98","author":"Moradian","year":"2020","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jcyt.2022.02.006","article-title":"CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma","volume":"24","author":"Schomer","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omtn.2026.102929_bib50","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nri1222","article-title":"Homing and cellular traffic in lymph nodes","author":"Von Andrian","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omtn.2026.102929_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtn.2026.102929_bib52","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","article-title":"Memory T cells: strategies for optimizing tumor immunotherapy","volume":"11","author":"Liu","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.omtn.2026.102929_bib53","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.annonc.2021.07.018","article-title":"Early-phenotype CAR-T cells for the treatment of pediatric cancers","volume":"32","author":"Meyran","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2026.102929_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-94804-7_1","article-title":"GADD45 in Stress Signaling, Cell Cycle Control, and Apoptosis","volume":"1360","author":"Humayun","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omtn.2026.102929_bib55","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.1038\/sj.onc.1205896","article-title":"ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth","volume":"21","author":"Fan","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.omtn.2026.102929_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.devcel.2017.11.024","article-title":"CCPG1 Is a Non-canonical Autophagy Cargo Receptor Essential for ER-Phagy and Pancreatic ER Proteostasis","volume":"44","author":"Smith","year":"2018","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2026.102929_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49289-5","article-title":"Phlda3 regulates beta cell survival during stress","volume":"9","author":"Bensellam","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.102929_bib58","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cell.2008.12.002","article-title":"PH Domain-Only Protein PHLDA3 Is a p53-Regulated Repressor of Akt","volume":"136","author":"Kawase","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2026.102929_bib59","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/mi.2014.84","article-title":"Dual Specificity Phosphatase 6 (DUSP6) regulates CD4+ T cell functions and restrains the spontaneous colitis in IL-10 deficient mice","volume":"8","author":"Bertin","year":"2015","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.omtn.2026.102929_bib60","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1186\/s12967-025-06628-7","article-title":"Expression signatures with specificity for type I and II IFN response and relevance for autoimmune diseases and cancer","volume":"23","author":"Aybey","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib61","doi-asserted-by":"crossref","first-page":"28504","DOI":"10.1074\/jbc.M204851200","article-title":"Identification of X-linked Inhibitor of Apoptosis-associated Factor-1 as an Interferon-stimulated Gene That Augments TRAIL Apo2L-induced Apoptosis","volume":"277","author":"Leaman","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2026.102929_bib62","doi-asserted-by":"crossref","first-page":"eabf0992","DOI":"10.1126\/scitranslmed.abf0992","article-title":"TRIB3 reduces CD8+ T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer","volume":"14","author":"Shang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2022.119265","article-title":"DDIT3\/CHOP mediates the inhibitory effect of ER stress on chondrocyte differentiation by AMPK\u03b1-SIRT1 pathway","volume":"1869","author":"Yu","year":"2022","journal-title":"Biochim. Biophys. Acta. Mol. Cell Res."},{"key":"10.1016\/j.omtn.2026.102929_bib64","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/cdd.2014.116","article-title":"Genotoxic stress\/p53-induced DNAJB9 inhibits the pro-apoptotic function of p53","volume":"22","author":"Lee","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omtn.2026.102929_bib65","doi-asserted-by":"crossref","first-page":"18160","DOI":"10.1038\/s41598-023-45197-x","article-title":"Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality","author":"von Auw","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2026.102929_bib66","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib67","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2026.102929_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780442","article-title":"T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2026.102929_bib69","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 Directly Inhibits CD8 + T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity In Brief Article Interleukin-10 Directly Inhibits CD8 + T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.102929_bib70","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.immuni.2021.11.004","article-title":"Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity","volume":"54","author":"Hanna","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2026.102929_bib71","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12032-015-0703-y","article-title":"The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116","volume":"32","author":"Dabkeviciene","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.omtn.2026.102929_bib72","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2026.102929_bib73","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine Release Syndrome: Current Perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.omtn.2026.102929_bib74","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2026.102929_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omtn.2026.102929_bib76","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.2174\/1381612821666150531164540","article-title":"Lipid-Based Nanocarriers for RNA Delivery","volume":"21","author":"Xue","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.omtn.2026.102929_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9040359","article-title":"Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines","volume":"9","author":"Thi","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.omtn.2026.102929_bib78","first-page":"275","article-title":"False discovery rates: a new deal","volume":"18","author":"Stephens","year":"2017","journal-title":"Biostatistics"}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253126001009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:28:14Z","timestamp":1794432494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253126001009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2162253126001009"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102929","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2026.102929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102929"}}